Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : 50% Gains Investing -- Ignore unavailable to you. Want to Upgrade?

To: IEarnedIt who wrote (14966)	1/24/2000 11:25:00 AM
From: Joe Copia	Respond to of 118717

VASO: Jan 18th Vasomedical (VASO:Nasdaq - news) reported its second-quarter earnings this afternoon, attracting 1.4 million shares of interest before the bell rang. It rose 7/32 to 1 9/16 during the day session, which is a 16.7% gain in the minuscule world of penny plays. Tonight, the company continued to trade heavily and post gains. It was last up 3/32 to 1 21/32 on 1.6 million shares on Island ECN, easily the most active issue. So, Vasomedical, huh? Yup. The medical-device maker is based in Westbury, N.Y., and is actively engaged in bringing its enhanced external counterpulsation system, or EECP, into the marketplace. These EECPs are designed to treat patients with coronary artery disease without using invasive surgery, thereby minimizing trauma to the delicate heart muscles. The technology behind the system is deceptively simple. It uses pressurized cuffs to squeeze veins and arteries in the legs to help circulate blood and then deflates these same cuffs when the heart pumps, reducing the load on the heart. A computer organizes the entire system to syncopate with a patient's heartbeat. Today Vasomedical announced that its second-quarter revenue from the sale and lease of these EECPs was $3 million, more than 700% better than last year's $364,000. Per-share earnings were nil in the same period, beating last year's 4-cent loss. The company said the reason for the increase in revenue and earnings was due to a decision by the Health Care Financing Administration, the government agency controlling Medicare, to cover the use of EECPs nationwide.